{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:12:57Z","timestamp":1793776377206,"version":"4.6.1"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"\n Importance<\/jats:title>\n Plasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To analyze the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n TRAILBLAZER-ALZ was a randomized, double-blind, placebo-controlled clinical trial conducted from December 18, 2017, to December 4, 2020, across 56 sites in the US and Canada. Exploratory biomarkers were prespecified with the post hoc addition of plasma glial fibrillary acidic protein and amyloid-\u03b2. Men and women aged 60 to 85 years with gradual and progressive change in memory function for at least 6 months were included. A total of 1955 participants were assessed for eligibility. Key eligibility criteria include Mini-Mental State Examination scores of 20 to 28 and elevated amyloid and intermediate tau levels.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Randomized participants received donanemab or placebo every 4 weeks for up to 72 weeks. The first 3 doses of donanemab were given at 700 mg and then increased to 1400 mg with blinded dose reductions as specified based on amyloid reduction.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Change in plasma biomarker levels after donanemab treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In TRAILBLAZER-ALZ, 272 participants (mean [SD] age, 75.2 [5.5] years; 145 [53.3%] female) were randomized. Plasma levels of phosphorylated tau\n 217<\/jats:sub>\n (pTau\n 217<\/jats:sub>\n ) and glial fibrillary acidic protein were significantly lower with donanemab treatment compared with placebo as early as 12 weeks after the start of treatment (least square mean change difference vs placebo, \u20130.04 [95% CI, \u20130.07 to \u20130.02];\n P<\/jats:italic>\n \u2009=\u2009.002 and \u20130.04 [95% CI, \u20130.07 to \u20130.01];\n P<\/jats:italic>\n \u2009=\u2009.01, respectively). No significant differences in plasma levels of amyloid-\u03b2 42\/40 and neurofilament light chain were observed between treatment arms at the end of treatment. Changes in plasma pTau\n 217<\/jats:sub>\n and glial fibrillary acidic protein were significantly correlated with the Centiloid percent change in amyloid (Spearman rank correlation coefficient [\n R<\/jats:italic>\n ]\u2009=\u20090.484 [95% CI, 0.359-0.592];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001 and\n R<\/jats:italic>\n \u2009=\u20090.453 [95% CI, 0.306-0.579];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001, respectively) following treatment. Additionally, plasma levels of pTau\n 217<\/jats:sub>\n and glial fibrillary acidic protein were significantly correlated at baseline and following treatment (\n R<\/jats:italic>\n \u2009=\u20090.399 [95% CI, 0.278-0.508],\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001 and\n R<\/jats:italic>\n \u2009=\u20090.393 [95% CI, 0.254-0.517];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n Significant reductions in plasma biomarkers pTau\n 217<\/jats:sub>\n and glial fibrillary acidic protein compared with placebo were observed following donanemab treatment in patients with early symptomatic Alzheimer disease. These easily accessible plasma biomarkers might provide additional evidence of Alzheimer disease pathology change through anti-amyloid therapy. Usefulness in assessing treatment response will require further evaluation.\n <\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03367403<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2022.3392","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T11:35:17Z","timestamp":1666006517000},"page":"1250","source":"Crossref","is-referenced-by-count":271,"title":["Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease"],"prefix":"10.1001","volume":"79","author":[{"given":"Michael J.","family":"Pontecorvo","sequence":"first","affiliation":[{"name":"Avid Radiopharmaceuticals, Philadelphia, Pennsylvania"},{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[{"name":"Avid Radiopharmaceuticals, Philadelphia, Pennsylvania"},{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha C.","family":"Burnham","sequence":"additional","affiliation":[{"name":"Avid Radiopharmaceuticals, Philadelphia, Pennsylvania"},{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Schade","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Dage","sequence":"additional","affiliation":[{"name":"Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shcherbinin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Collins","sequence":"additional","affiliation":[{"name":"Avid Radiopharmaceuticals, Philadelphia, Pennsylvania"},{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Sims","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Mintun","sequence":"additional","affiliation":[{"name":"Avid Radiopharmaceuticals, Philadelphia, Pennsylvania"},{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi220063r1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.v17.3","article-title":"2021 Alzheimer\u2019s disease facts and figures.","volume":"17","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"22","key":"noi220063r2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225536","article-title":"When does Alzheimer\u2019s disease really start? the role of biomarkers.","volume":"20","author":"Lloret","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"noi220063r3","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease.","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"1","key":"noi220063r4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation.","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"2","key":"noi220063r5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease.","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"issue":"11","key":"noi220063r6","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease.","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"issue":"8","key":"noi220063r7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"noi220063r8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease.","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"11","key":"noi220063r9","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u00df but not tau pathology in Alzheimer\u2019s disease.","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"1","key":"noi220063r10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","article-title":"Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration.","volume":"7","author":"Ashton","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"noi220063r11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease.","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi220063r12","doi-asserted-by":"publisher","first-page":"9736","DOI":"10.1038\/s41598-021-89004-x","article-title":"Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer\u2019s disease.","volume":"11","author":"Thijssen","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"noi220063r13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u00df-amyloid status.","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"noi220063r14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.v17.S5","article-title":"Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u00df42\/A\u00df40 and p-tau.","author":"Janelidze","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi220063r15","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.v7.1","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease.","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"noi220063r16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging.","volume":"8","author":"Lowe","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"18","key":"noi220063r17","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"noi220063r18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"noi220063r19","article-title":"Integrated Alzheimer\u2019s Disease Rating Scale: Clinically meaningful change estimates.","volume":"8","author":"Wessels","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"noi220063r20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease.","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"noi220063r21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease.","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"noi220063r22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE).","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"noi220063r23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/glia.v68.5","article-title":"Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytes.","volume":"68","author":"Li","year":"2020","journal-title":"Glia"},{"issue":"12","key":"noi220063r24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"issue":"12","key":"noi220063r25","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170228","article-title":"The role of astrocytes in amyloid production and Alzheimer\u2019s disease.","volume":"7","author":"Frost","year":"2017","journal-title":"Open Biol"},{"issue":"11","key":"noi220063r26","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma amyloid-\u00df 42\/40 assays in Alzheimer disease.","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi220063r27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","article-title":"A blood-based diagnostic test incorporating plasma A\u00df42\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.","volume":"16","author":"West","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"10","key":"noi220063r28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders.","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"noi220063r29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2017.04.027","article-title":"Plasma neurofilament light chain levels in Alzheimer\u2019s disease.","volume":"650","author":"Zhou","year":"2017","journal-title":"Neurosci Lett"},{"issue":"6","key":"noi220063r30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.v18.6","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.","volume":"18","author":"Syrjanen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"7","key":"noi220063r31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease.","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"issue":"8","key":"noi220063r32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials.","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"noi220063r33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40478-021-01307-2","article-title":"Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.","volume":"10","author":"Wennstr\u00f6m","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"16","key":"noi220063r34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u00df deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease.","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci Adv"},{"issue":"1","key":"noi220063r35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","article-title":"Astrocytes: biology and pathology.","volume":"119","author":"Sofroniew","year":"2010","journal-title":"Acta Neuropathol"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2797022\/jamaneurology_pontecorvo_2022_oi_220063_1670426930.14644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T11:01:12Z","timestamp":1670842872000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2797022"}},"subtitle":["A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}